APA (7th ed.) Citation

Rob, F., Kojanová, M., Hercogová, J. T., Baláž, M., Horažďovský, J., Vantuchová, Y., . . . Gkalpakiotis, S. (2026). Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis. International Journal of Dermatology, 65(5), 1061. https://doi.org/10.1111/ijd.70180

Chicago Style (17th ed.) Citation

Rob, Filip, et al. "Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis." International Journal of Dermatology 65, no. 5 (2026): 1061. https://doi.org/10.1111/ijd.70180.

MLA (9th ed.) Citation

Rob, Filip, et al. "Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis." International Journal of Dermatology, vol. 65, no. 5, 2026, p. 1061, https://doi.org/10.1111/ijd.70180.